New research presented at the Society for Cardiovascular Angiography & Interventions 2026 Scientific Sessions shows tirzepatide significantly lowers cardiovascular risk in high-risk patients undergoing heart procedures, outperforming older GLP-1 drugs like dulaglutide in reducing heart attacks, heart failure exacerbations, and mortality.
In a study of 1,281 patients with type 2 diabetes who underwent percutaneous coronary intervention, those taking tirzepatide had a 54% lower risk of major cardiovascular events one month post-procedure compared to dulaglutide users, with benefits persisting and even increasing at one year, including a 62% reduction in mortality.
Patients receiving tirzepatide also experienced lower rates of acute myocardial infarction (RR 0.47), heart failure exacerbation (RR 0.54), and ventricular arrhythmias (RR 0.56) at one month, with sustained reductions in MACE, AMI, and heart failure exacerbation at one year, alongside reduced stroke (RR 0.56) and cardiac arrest (RR 0.32) risks.
A second study focused on transcatheter aortic valve replacement found tirzepatide users had roughly a 30% lower risk of major cardiovascular problems following surgery, whereas heart attack rates remained similar between groups, suggesting differential effects across vascular territories.
“Tirzepatide consistently reduced major cardiovascular events and mortality across multiple time points, which clinicians should actively consider when selecting therapies,” said Revati Varma, internal medicine resident at Cook County Hospital and author of the PCI study, in a statement released by the conference organizers.
The findings build on tirzepatide’s established dual action as a GIP and GLP-1 receptor agonist, which improves glycemic control and promotes weight loss averaging around 20% over a year—mechanisms long linked to cardiovascular benefit but now demonstrated directly in acute interventional settings.
While prior research confirmed GLP-1 agonists’ heart-protective effects broadly, these studies are among the first to evaluate impact specifically in patients undergoing percutaneous coronary intervention and transcatheter aortic valve replacement, filling a critical gap in real-world evidence for high-risk populations.
Srihari S. Naidu, MD, MSCAI, SCAI President, noted that this year’s Scientific Sessions provide an important platform to discuss how metabolic therapies like tirzepatide can improve outcomes in transcatheter cardiovascular interventions, marking an evolution in cardiometabolic care beyond glucose and weight management.
Although tirzepatide is already the most effective obesity drug of its kind on the market, these results position it as a potential dual-purpose therapy for patients with obesity or diabetes who also face elevated cardiovascular risk due to structural heart disease.
The research does not clarify whether cardiovascular benefits stem primarily from weight loss, metabolic improvement, or direct vascular effects, leaving open questions about mechanism that future studies will need to address.
How does tirzepatide compare to older GLP-1 drugs like dulaglutide in reducing heart risk after procedures?
Tirzepatide outperformed dulaglutide in reducing major cardiovascular events, heart attacks, heart failure exacerbation, ventricular arrhythmias, mortality, stroke, and cardiac arrest in patients undergoing percutaneous coronary intervention, with risk reductions ranging from 32% to 62% depending on outcome and time point.
Are the cardiovascular benefits of tirzepatide limited to weight loss and blood sugar control?
The sources do not specify whether benefits are due to weight loss, metabolic effects, or direct actions on the heart or vessels; researchers note that while prior studies link GLP-1 agonists to cardiovascular protection, the exact mechanism in interventional settings remains under investigation.
